Navigation Links
Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration

Mechelen, Belgium and Bethesda, Maryland, USA; 29 November 2007 Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, announced today a new collaboration aimed at discovering new treatments for cystic fibrosis. This new agreement between CFFT and Galapagos BioFocus DPI service division is worth up to 5.5 million euros ($8.1 million U.S. dollars) for Galapagos.

The collaboration will combine two key strengths of BioFocus DPI expertise in natural product drug discovery and screening in cells derived from patients. Specifically, the collaboration aims to identify small molecules derived from natural sources that improve the function of a defective protein found in people who have cystic fibrosis. The protein is called CFTR - cystic fibrosis transmembrane conductance regulator. To advance the search for a cure for cystic fibrosis, CFFT funds promising scientific research in the pharmaceutical and biotechnology industry and academia worldwide.

Under the terms of the agreement, Galapagos stands to receive up to 1.6 million ($2.4 million) in upfront and research fees over the next two years, and up to 3.8 million ($5.7 million) in success-based milestone payments, should certain clinical development criteria be met.

This drug discovery collaboration is in addition to an ongoing target discovery program established between CFFT and BioFocus DPI in April 2005.

We are excited to take advantage of the innovative drug discovery approach developed by BioFocus DPI and the companys extensive expertise in natural compounds, said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. By exploring compounds derived from natural sources, our goal is to increase the number and diversity of drug candidates in development to treat cystic fibrosis.

The CFFT drug discovery collaboration is a prime example of the kind of innovation we aimed to achieve through our acquisition strategy, said Onno van de Stolpe, CEO of Galapagos. We have seen a growing interest in natural product based drug discovery since acquiring these capabilities last year. By combining this expertise with our know-how in cell-based screening, we are confident that we will contribute to the advancement of CFFTs drug discovery program in novel ways.


Contact: Lily Mccutchan
Cystic Fibrosis Foundation

Related biology news :

1. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
2. Balzan Foundation announces 2007 winners
3. Keck Foundation funds study of biological interactions with nanomaterials
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
6. Simons Foundation awards Emory scientists $3M for autism gene research
7. Arizona State University launches biofuel initiative with BP and Science Foundation Arizona
8. Life-saving clean water project secures $13M from Bill & Melinda Gates Foundation
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. LaserCard Corporation Announces Expansion of Middle East Project
11. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
Post Your Comments:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: